Cargando…
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET
BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly tri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538506/ https://www.ncbi.nlm.nih.gov/pubmed/22682112 http://dx.doi.org/10.1186/2191-219X-2-28 |
_version_ | 1782254950195134464 |
---|---|
author | Notni, Johannes Pohle, Karolin Wester, Hans-Jürgen |
author_facet | Notni, Johannes Pohle, Karolin Wester, Hans-Jürgen |
author_sort | Notni, Johannes |
collection | PubMed |
description | BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have been shown to possess superior (68)Ga binding ability. Here, we report on the efficiency, reproducibility, and achievable specific activity for fully automated (68)Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates. FINDINGS: Compared to NOTA- and DOTA-peptides, achievable specific activity (A(S)) for TRAP-peptide is approximately 10 and 20 times higher, respectively. A(S) values in the range of 5,000 GBq/μmol were routinely obtained using 1 GBq of (68)Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate. The TRAP-peptide could be (68)Ga-labeled with excellent reproducibility and > 95% radiochemical yield for precursor amounts as low as 1 nmol. CONCLUSIONS: High (68)Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures. The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass content in tracer formulations. |
format | Online Article Text |
id | pubmed-3538506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-35385062013-01-08 Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET Notni, Johannes Pohle, Karolin Wester, Hans-Jürgen EJNMMI Res Short Communication BACKGROUND: Currently, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-tetraacetic acid (DOTA)-peptides are the most widely used class of (68)Ga radiotracers for PET, although DOTA is not optimal for (68)Ga complexation. More recently, 1,4,7-triazacyclononane-triacetic acid (NOTA) and particularly triazacyclononane-phosphinate (TRAP) chelators have been shown to possess superior (68)Ga binding ability. Here, we report on the efficiency, reproducibility, and achievable specific activity for fully automated (68)Ga labeling of DOTA-, NOTA-, and TRAP-peptide conjugates. FINDINGS: Compared to NOTA- and DOTA-peptides, achievable specific activity (A(S)) for TRAP-peptide is approximately 10 and 20 times higher, respectively. A(S) values in the range of 5,000 GBq/μmol were routinely obtained using 1 GBq of (68)Ga, equivalent to 0.11 μg of cold mass for a 185-MBq patient dose of a 3-kDa conjugate. The TRAP-peptide could be (68)Ga-labeled with excellent reproducibility and > 95% radiochemical yield for precursor amounts as low as 1 nmol. CONCLUSIONS: High (68)Ga labeling efficiency of TRAP-peptides could facilitate realization of kit labeling procedures. The good reproducibility of the automated synthesis is of relevance for GMP production, and the possibility to provide very high specific activities offers a high degree of safety in first clinical trials, due to reduction of cold mass content in tracer formulations. Springer 2012-06-09 /pmc/articles/PMC3538506/ /pubmed/22682112 http://dx.doi.org/10.1186/2191-219X-2-28 Text en Copyright ©2012 Notni et al. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Notni, Johannes Pohle, Karolin Wester, Hans-Jürgen Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title | Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title_full | Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title_fullStr | Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title_full_unstemmed | Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title_short | Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET |
title_sort | comparative gallium-68 labeling of trap-, nota-, and dota-peptides: practical consequences for the future of gallium-68-pet |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538506/ https://www.ncbi.nlm.nih.gov/pubmed/22682112 http://dx.doi.org/10.1186/2191-219X-2-28 |
work_keys_str_mv | AT notnijohannes comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet AT pohlekarolin comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet AT westerhansjurgen comparativegallium68labelingoftrapnotaanddotapeptidespracticalconsequencesforthefutureofgallium68pet |